Inovio Pharmaceuticals Inc
INO1.460USD
+0.030+2.10%
交易中 （美东）报价延迟15分钟
53.54M总市值
亏损市盈率 TTM
关于 Inovio Pharmaceuticals Inc 公司
Inovio Pharmaceuticals, Inc. 是一家临床阶段的生物技术公司。该公司专注于开发和商业化脱氧核糖核酸 (DNA) 药物，以帮助治疗和预防与人乳头瘤病毒 (HPV)、癌症和传染病相关的疾病。其 DNA 药物管线包括用于治疗 HPV 相关复发性呼吸道乳头状瘤病 (RRP) 的 INO-3107；用于治疗 HPV 相关口咽鳞状细胞癌 (OPSCC) 的 INO-3112；用于治疗肛门或肛周 HSIL 的 VGX-3100；用于治疗多形性胶质母细胞瘤 (GBM) 的 INO-5401，以及用于治疗多形性胶质母细胞瘤 (GBM) 的 INO-5401。其主要候选药物是用于治疗 RRP 的 INO-3107，RRP 是一种由 HPV 感染引起的罕见且使人衰弱的呼吸道疾病。该公司的 DNA 药物平台由 DNA 质粒和 CELLECTRA 设备组成，后者用于将 DNA 质粒输送到细胞中。该公司的 CELLECTRA 设备组合包括两种型号。
公司简介
公司代码INO
公司名称Inovio Pharmaceuticals Inc
上市日期Dec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
员工数量134
证券类型Ordinary Share
年结日Dec 08
公司地址660 W. Germantown Pike
城市PLYMOUTH MEETING
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编19462
电话18584103134
网址https://www.inovio.com/
公司代码INO
上市日期Dec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+32.11%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+33.04%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
收入明细
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
65.34K
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月27日 周日
更新时间: 7月27日 周日
持股股东
股东类型
持股股东
持股股东
占比
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
持股股东
持股股东
占比
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
股东类型
持股股东
占比
Investment Advisor
10.80%
Hedge Fund
6.99%
Investment Advisor/Hedge Fund
5.77%
Research Firm
3.06%
Individual Investor
0.56%
Bank and Trust
0.30%
Venture Capital
0.13%
Pension Fund
0.02%
Other
72.36%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
302
14.08M
27.64%
-1.14M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
2023Q2
462
6.56M
29.43%
-5.01M
2023Q1
491
10.80M
49.36%
-1.98M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Deep Track Capital LP
3.12M
6.12%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.15M
4.22%
+393.45K
+22.37%
Mar 31, 2025
The Vanguard Group, Inc.
2.03M
3.98%
+355.37K
+21.23%
Mar 31, 2025
BofA Global Research (US)
1.30M
2.56%
+664.00K
+103.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
846.80K
1.66%
+218.30K
+34.73%
Mar 31, 2025
Stonepine Capital Management, LLC
518.33K
1.02%
-531.67K
-50.64%
Mar 31, 2025
State Street Global Advisors (US)
514.15K
1.01%
+9.84K
+1.95%
Mar 31, 2025
Northern Trust Investments, Inc.
461.70K
0.91%
+242.90K
+111.02%
Mar 31, 2025
Susquehanna International Group, LLP
194.37K
0.38%
+152.20K
+360.91%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 3000 ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
DFA Dimensional US Core Equity Market ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.01%
iShares Russell 3000 ETF
占比0%
Invesco RAFI US 1500 Small-Mid ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
iShares Biotechnology ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
公告日期
类型
比率
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
